Philip R. Debruyne, MD, PhD, MSc, DABCP (CP), FRCP(Glasg), FCP is a Consultant Medical Oncologist, Clinical Pharmacologist & Lead Clinician at the OECI-designated Kortrijk Cancer Centre of az groeninge (Kortrijk, Belgium; since 2008) with as specialty interests : gynaecologic and urologic cancers, early clinical trials and geriatric oncology. Since 2016 he serves as an Honorary Visiting Professor of Anglia Ruskin University (Medical Technology Research Centre (MTRC), School of Life Sciences, Cambridge, UK), and since 2021 as an Honorary Associate Professor (Reader) in Cancer Care and since 2024 as an Honorary Clinical Professor of Cancer Pharmacology at the School of Nursing and Midwifery (Faculty of Health) of the University of Plymouth, UK.
He was born October 5th 1971 in Bruges. He received the degrees: Physician (Ghent University; 1996), standard ECFMG certificate + FSMB USMLE step 3 (MD equivalent; 1997 & 2004; USA), PhD in Medical Sciences (Ghent University; 2002) and MSc in Pharmacology (Human Investigation; Thomas Jefferson University, Philadelphia, USA; 2005). During and after completing an internship and residency training at Ghent University Hospital (1996-2002), he spent: 4 years (1997-2001) at the Laboratory of Experimental Cancer Research of the Department of Radiotherapy and Nuclear Medicine (Ghent University) as a Research Associate, 2 years (2002-2004) at the Division of Clinical Pharmacology of the Sidney Kimmel Cancer Center at Thomas Jefferson University (Philadelphia, USA) as a Post-doctoral Fellow in Clinical Pharmacology and two years at the Department of General Medical Oncology of the LeuvenUniversity Hospitals as a Clinical Fellow in Medical Oncology. He obtained board certifications in Internal Medicine (Ghent University; 2004), Clinical Pharmacology (American Board of Clinical Pharmacology; 2005) and Medical Oncology (Leuven University; 2006). Prior to joining az groeninge Hospital in 2008, he held the positions of Clinical Senior Lecturer in Medical Oncology (Clinical Trials; 2006-2008) in the Department of Cancer Sciences and Molecular Pathology of the University of Glasgow (UK) and the position of Honorary Consultant in Medical Oncology at the Beatson West of Scotland Cancer Centre in Glasgow (2006-2008). From 2013 to 2016 he was an Honorary Senior Fellow with the School of Health & Social Care of the University of Greenwich in London (UK)) were he led the Ageing & Cancer Research Cluster within the Centre for Positive Ageing.
Dr Debruyne was the recipient of a Sportvereniging tegen Kanker award (1998), the the two-year Merck Sharp & Dohme International Fellowship in Clinical Pharmacology Award (2002-2004), an Honorary Belgian American Educational Foundation (BAEF) Fellowship (2003), the 5th Pfizer Oncology Award 2020 and grants from: Bijzonder Onderzoeksfonds (BOF) Universiteit Gent, Vlaamse Kanker Liga, West Research Endowment Fund (UK), Pfizer (educational grant), Federale Overheidsdienst Volksgezondheid, Veiligheid van de VoedselKeten en Leefmilieu (Belgian Federal Government/National Cancer Plan), Kom Op Tegen Kanker (KOTK, Belgium), King Baudouin Foundation (KBF, Belgium) and Belgian Foundation against Cancer. He is a Fellow of the Royal College of Physicians & Surgeons of Glasgow qua Physician (FRCP), a Fellow of the American College of Clinical Pharmacology (FCP) and member of numerous scientific societies and cooperative groups such as the European Organisation for Research and Treatment of Cancer (EORTC QoL group; EORTC GUCG representative in Older Adult Council, OAC), Belgian Society of Medical Oncology (BSMO; Survivorship Task Force) and a former member of both the Committee and Panel of the National Cancer Research Network (NCRN; UK) Chemotherapy and Pharmacy Advisory Service (CPAS). He was founding board member of the Kortrijk Oncology Fund charity within the King Baudouin Foundation (KBF). He previously served as associate editor of European Journal of Cancer Careand BMC Pharmacology and Toxicologyand as guest editor for other journals. He serves since 2021 as (Substitute) Board Member (with experience in phase 1 trials) of the Clinical Trials College (Federal Public Service (FPS) Health, Food chain safety and Environment, Belgium).
He was born October 5th 1971 in Bruges. He received the degrees: Physician (Ghent University; 1996), standard ECFMG certificate + FSMB USMLE step 3 (MD equivalent; 1997 & 2004; USA), PhD in Medical Sciences (Ghent University; 2002) and MSc in Pharmacology (Human Investigation; Thomas Jefferson University, Philadelphia, USA; 2005). During and after completing an internship and residency training at Ghent University Hospital (1996-2002), he spent: 4 years (1997-2001) at the Laboratory of Experimental Cancer Research of the Department of Radiotherapy and Nuclear Medicine (Ghent University) as a Research Associate, 2 years (2002-2004) at the Division of Clinical Pharmacology of the Sidney Kimmel Cancer Center at Thomas Jefferson University (Philadelphia, USA) as a Post-doctoral Fellow in Clinical Pharmacology and two years at the Department of General Medical Oncology of the LeuvenUniversity Hospitals as a Clinical Fellow in Medical Oncology. He obtained board certifications in Internal Medicine (Ghent University; 2004), Clinical Pharmacology (American Board of Clinical Pharmacology; 2005) and Medical Oncology (Leuven University; 2006). Prior to joining az groeninge Hospital in 2008, he held the positions of Clinical Senior Lecturer in Medical Oncology (Clinical Trials; 2006-2008) in the Department of Cancer Sciences and Molecular Pathology of the University of Glasgow (UK) and the position of Honorary Consultant in Medical Oncology at the Beatson West of Scotland Cancer Centre in Glasgow (2006-2008). From 2013 to 2016 he was an Honorary Senior Fellow with the School of Health & Social Care of the University of Greenwich in London (UK)) were he led the Ageing & Cancer Research Cluster within the Centre for Positive Ageing.
Dr Debruyne was the recipient of a Sportvereniging tegen Kanker award (1998), the the two-year Merck Sharp & Dohme International Fellowship in Clinical Pharmacology Award (2002-2004), an Honorary Belgian American Educational Foundation (BAEF) Fellowship (2003), the 5th Pfizer Oncology Award 2020 and grants from: Bijzonder Onderzoeksfonds (BOF) Universiteit Gent, Vlaamse Kanker Liga, West Research Endowment Fund (UK), Pfizer (educational grant), Federale Overheidsdienst Volksgezondheid, Veiligheid van de VoedselKeten en Leefmilieu (Belgian Federal Government/National Cancer Plan), Kom Op Tegen Kanker (KOTK, Belgium), King Baudouin Foundation (KBF, Belgium) and Belgian Foundation against Cancer. He is a Fellow of the Royal College of Physicians & Surgeons of Glasgow qua Physician (FRCP), a Fellow of the American College of Clinical Pharmacology (FCP) and member of numerous scientific societies and cooperative groups such as the European Organisation for Research and Treatment of Cancer (EORTC QoL group; EORTC GUCG representative in Older Adult Council, OAC), Belgian Society of Medical Oncology (BSMO; Survivorship Task Force) and a former member of both the Committee and Panel of the National Cancer Research Network (NCRN; UK) Chemotherapy and Pharmacy Advisory Service (CPAS). He was founding board member of the Kortrijk Oncology Fund charity within the King Baudouin Foundation (KBF). He previously served as associate editor of European Journal of Cancer Careand BMC Pharmacology and Toxicologyand as guest editor for other journals. He serves since 2021 as (Substitute) Board Member (with experience in phase 1 trials) of the Clinical Trials College (Federal Public Service (FPS) Health, Food chain safety and Environment, Belgium).
Publications
Key publications
Key publications are highlighted
Journals
Articles
(2023) 'Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201' Annals of Oncology 35, (2) 200-210 Publisher Site , DOI
(2023) 'End-of-Life Care in the Last Three Months before Death in Older Patients with Cancer in Belgium: A Large Retrospective Cohort Study Using Data Linkage' Cancers 15, (13) 3349-3349 Publisher Site , DOI
(2023) 'Long-term health-care utilisation in older patients with cancer and the association with the Geriatric 8 screening tool: a retrospective analysis using linked clinical and population-based data in Belgium' The Lancet Healthy Longevity 4, (7) e326-e336 Publisher Site , DOI
(2023) 'Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer' Gynecologic Oncology 174, 80-88 Publisher Site , DOI
(2023) 'Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study' ESMO Open 8, (2) 100877-100877 Publisher Site , DOI
(2023) 'Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis' Clinical Genitourinary Cancer 21, (4) 442-451 Publisher Site , DOI
(2023) 'Editorial: Clinical cancer research in vulnerable populations' Frontiers in Oncology 13, , DOI Open access
(2023) 'Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes' Journal of Geriatric Oncology 14, (2) 101428-101428 Publisher Site , DOI
(2023) 'Diagnostic Performance of Screening Tools for Depressive Symptoms in Vulnerable Older Patients with Cancer Undergoing Comprehensive Geriatric Assessment (CGA): Results from the SCREEN Pilot Study' Current Oncology 30, (2) 1805-1817 , DOI Open access
(2023) 'Practical Implementation of the Comprehensive Geriatric
Assessment to Optimise Care for Older Adults with Cancer' Geriatrics 8, (1) , DOI Open access
(2022) 'Psychosocial Care after Cancer Diagnosis: Recent Advances and Challenges' Cancers 14, (23) 5882-5882 , DOI Open access
(2022) 'Incidence of falls and fall-related injuries and their predictive factors in frail older persons with cancer: a multicenter study' BMC Geriatrics 22, (1) Publisher Site , DOI
(2022) 'Functional status in older patients with cancer and a frailty risk profile: A multicenter observational study' Journal of Geriatric Oncology 13, (8) 1162-1171 Publisher Site , DOI
(2022) 'Dual time point imaging in locally advanced head and neck cancer to assess residual nodal disease after chemoradiotherapy' EJNMMI Research 12, (1) Publisher Site , DOI
(2022) 'Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire' Journal of Cancer Survivorship 17, (4) 1111-1130 Publisher Site , DOI
(2021) 'Oncologic Home-Hospitalization Delivers a High-Quality and Patient-Centered Alternative to Standard Ambulatory Care: Results of a Randomized-Controlled Equivalence Trial' JCO Global Oncology (7) 1564-1571 Publisher Site , DOI
(2021) 'Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study' Acta Oncologica 61, (1) 22-29 Publisher Site , DOI
(2021) 'A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial' European Journal of Cancer 158, 17-26 Publisher Site , DOI
(2021) 'Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors' Current Oncology 28, (5) 3227-3239 Publisher Site , DOI
(2021) 'A randomised wait-list controlled trial to evaluate Emotional Freedom Techniques for self-reported cancer-related cognitive impairment in cancer survivors (EMOTICON)' EClinicalMedicine 39, 101081-101081 Publisher Site , DOI
(2021) 'Acupuncture as a Complementary Therapy for Cancer Care: Acceptability and Preferences of Patients and Informal Caregivers' Journal of Acupuncture and Meridian Studies 14, (2) 67-74 , DOI Open access
(2021) 'Pain Medication Adherence in Patients with Cancer: A Pragmatic Review' Pain Medicine 23, (4) 782-798 Publisher Site , DOI
(2021) 'C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab' Urologic Oncology: Seminars and Original Investigations 39, (4) 239.e17-239.e25 Publisher Site , DOI
(2020) 'Unplanned hospitalizations in older patients with cancer: Occurrence and predictive factors' Journal of Geriatric Oncology 12, (3) 368-374 Publisher Site , DOI
(2020) 'Developing and evaluating a participatory arts programme for cancer patients and their caregivers' Acta Clinica Belgica 77, (1) 18-24 Publisher Site , DOI
(2020) 'Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors' Urologic Oncology: Seminars and Original Investigations 38, (8) 686.e1-686.e9 Publisher Site , DOI
(2020) 'The prognostic value of patient-reported Health-Related Quality of Life and Geriatric Assessment in predicting early death in 6769 older (≥70 years) patients with different cancer tumors' Journal of Geriatric Oncology 11, (6) 926-936 Publisher Site , DOI
(2020) 'Quality of blood samples collected at home does not affect clinical decision making for the administration of systemic cancer treatment' Scandinavian Journal of Clinical and Laboratory Investigation 80, (3) 215-221 Publisher Site , DOI
(2020) 'Effectiveness of Adjunctive Analgesics in Head and Neck Cancer Patients Receiving Curative (Chemo-) Radiotherapy: A Systematic Review' Pain Medicine 22, (1) 152-164 Publisher Site , DOI
(2020) 'Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study' European Journal of Nuclear Medicine and Molecular Imaging 47, (5) 1075-1082 Publisher Site , DOI
(2020) 'PSMA expression on neovasculature of solid tumors' HISTOLOGY AND HISTOPATHOLOGY 35, (9) 919-927 , DOI
(2019) 'Underrepresentation of vulnerable older patients with cancer in phase II and III oncology registration trials: A case-control study' Journal of Geriatric Oncology 11, (2) 320-326 Publisher Site , DOI
(2019) 'Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial' The Lancet Oncology 20, (6) 862-876 Publisher Site , DOI
(2019) 'Shifting specialized oncological care from hospital- to home-setting: is there support among patients, specialists and general practitioners?' Acta Clinica Belgica 75, (4) 250-257 Publisher Site , DOI
(2019) 'Health related quality of life in older patients with solid tumors and prognostic factors for decline' Journal of Geriatric Oncology 10, (6) 895-903 Publisher Site , DOI
(2019) 'An observational pilot study to evaluate the feasibility and quality of oncological home-hospitalization' European Journal of Oncology Nursing 40, 44-52 Publisher Site , DOI
(2019) 'Detection of alcohol abuse in older patients with cancer: The integration of alcohol screening questionnaires in the comprehensive geriatric assessment' Journal of Geriatric Oncology 10, (5) 819-823 Publisher Site , DOI
(2019) 'Subjective, but not objective, cognitive complaints impact long-term quality of life in cancer patients' Journal of Psychosocial Oncology 37, (4) 427-440 Publisher Site , DOI
(2019) 'The added value of an assessment of the patient's hand grip strength to the comprehensive geriatric assessment in G8-abnormal older patients with cancer in routine practice' Journal of Geriatric Oncology 10, (6) 931-936 Publisher Site , DOI
(2018) 'Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery' Quality of Life Research 28, (3) 663-676 Publisher Site , DOI
(2018) 'Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib' Clinical Genitourinary Cancer 17, (2) e235-e246 Publisher Site , DOI
(2018) 'Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium' Annals of Oncology 29, (9) 1987-1994 Publisher Site , DOI
(2018) 'Screening Methods for Age-Related Hearing Loss in Older Patients with Cancer: A Review of the Literature' Geriatrics 3, (3) 48-48 Publisher Site , DOI
(2018) 'ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib' Acta Clinica Belgica 74, (3) 180-188 Publisher Site , DOI
(2018) 'Organization, quality and cost of oncological home-hospitalization: A systematic review' Critical Reviews in Oncology/Hematology 126, 145-153 Publisher Site , DOI
(2018) 'Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy' Annals of Oncology 29, (3) 737-743 Publisher Site , DOI
(2017) 'The use of uHear™ to screen for hearing loss in older patients with cancer as part of a comprehensive geriatric assessment' Acta Clinica Belgica 73, (2) 132-138 Publisher Site , DOI
(2017) 'Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors' Supportive Care in Cancer 26, (3) 869-878 Publisher Site , DOI
(2017) 'Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy in Locally Advanced Head-and-Neck Squamous Cell Cancer: The ECLYPS Study' Journal of Clinical Oncology 35, (30) 3458-3464 Publisher Site , DOI
(2017) 'The distress thermometer predicts subjective, but not objective, cognitive complaints six months after treatment initiation in cancer patients' Journal of Psychosocial Oncology 35, (6) 741-757 Publisher Site , DOI
(2016) 'Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer' New England Journal of Medicine 375, (22) 2154-2164 Publisher Site , DOI
(2016) 'PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck' Oral Oncology 61, 31-40 Publisher Site , DOI
(2016) 'Predictors of baseline cancer-related cognitive impairment in cancer patients scheduled for a curative treatment' Psycho-Oncology 26, (5) 632-639 Publisher Site , DOI
(2016) 'Implementation of uHear™ - an iOS-based application to screen for hearing loss - in older patients with cancer undergoing a comprehensive geriatric assessment' Journal of Geriatric Oncology 7, (2) 126-133 Publisher Site , DOI
(2015) 'G-8 indicates overall and quality-adjusted survival in older head and neck cancer patients treated with curative radiochemotherapy' BMC Cancer 15, (1) Publisher Site , DOI
(2015) 'Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor' Acta Oncologica 55, (3) 329-340 Publisher Site , DOI
(2015) 'Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group' Gynecologic Oncology 138, (2) 278-284 Publisher Site , DOI
(2015) 'Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy' Targeted Oncology 10, (4) 583-596 Publisher Site , DOI
(2015) 'A Belgian survey on geriatric assessment in oncology focusing on large-scale implementation and related barriers and facilitators' The Journal of nutrition, health and aging 20, (1) 60-70 Publisher Site , DOI
(2015) '<i>Echium plantagineum</i> (echium) does not prevent weight loss in head and neck cancer patients' Focus on Alternative and Complementary Therapies 20, (2) 117-119 Publisher Site , DOI
(2015) 'Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer' BMC Pharmacology and Toxicology 16, (1) Publisher Site , DOI
(2015) 'Integration of geriatric oncology in daily multidisciplinary cancer care: the time is now' European Journal of Cancer Care 24, (2) 143-146 Publisher Site , DOI
(2015) 'Optimisation of pharmacy content in clinical cancer research protocols: Experience of the United Kingdom Chemotherapy and Pharmacy Advisory Service' Clinical Trials 12, (3) 257-264 Publisher Site , DOI
(2014) 'Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma' Annals of Oncology 26, (2) 378-385 Publisher Site , DOI
(2014) 'Echium oil is not protective against weight loss in head and neck cancer patients undergoing curative radio(chemo)therapy: a randomised-controlled trial' BMC Complementary and Alternative Medicine 14, (1) Publisher Site , DOI
(2014) 'Prospective non-interventional multicentre observational trial of first-line anti-cancer treatment in patients with metastatic renal cell cancer in Belgium' Acta Clinica Belgica 69, (5) 335-340 Publisher Site , DOI
(2014) 'Themes for our journal: 2014-2016' European Journal of Cancer Care 23, (3) 285-287 Publisher Site , DOI
(2014) 'Validation of the Freund Clock Drawing Test as a screening tool to detect cognitive dysfunction in elderly cancer patients undergoing comprehensive geriatric assessment' Psycho-Oncology 23, (10) 1172-1177 Publisher Site , DOI
(2014) '[(Added) Value of a clinical pharmacist in the oncology department and optimalisation of the applicability of geriatric tools assessing potential inappropriate medication use in geriatric patients (Drug Burden Index and de Beers criteria)]' J Pharm Belg (1) 28-36
(2014) 'Serial comprehensive geriatric assessment in elderly head and neck cancer patients undergoing curative radiotherapy identifies evolution of multidimensional health problems and is indicative of quality of life' European Journal of Cancer Care 23, (3) 401-412 Publisher Site , DOI
(2014) 'Prognostic impact of baseline serum <scp>C</scp>‐reactive protein in patients with metastatic renal cell carcinoma (<scp>RCC</scp>) treated with sunitinib' BJU International 114, (1) 81-89 Publisher Site , DOI
(2013) 'Appointment of new Editor-in-Chief: a time for reflection upon our past and future' European Journal of Cancer Care 22, (5) 561-563 Publisher Site , DOI
(2013) 'Omega-3 fatty acids: physiology, biological sources and potential applications in supportive cancer care' Phytochemistry Reviews 13, (1) 223-244 Publisher Site , DOI
(2013) 'A call for rigorous research and transparent study reporting …' European Journal of Cancer Care 22, (4) 421-422 Publisher Site , DOI
(2013) 'Prognostic impact of baseline serum C-reactive protein in metastatic renal cell carcinoma treated with sunitinib' Journal of Clinical Oncology 31, (6_suppl) 425-425 Publisher Site , DOI
(2012) 'Use of the Freund Clock Drawing Test within the Mini-Cog as a screening tool for cognitive impairment in elderly patients with or without cancer' Journal of Geriatric Oncology 4, (2) 174-182 Publisher Site , DOI
(2012) 'Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases' British Journal of Cancer 107, (10) 1665-1671 Publisher Site , DOI
(2012) 'BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years' British Journal of Cancer 106, (6) 1234-1238 Publisher Site , DOI
(2012) 'What is the best treatment option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI-TKI or TKI-mTORi? A European retrospective study' Journal of Clinical Oncology 30, (5_suppl) 375-375 Publisher Site , DOI
(2012) 'Experience with Lexicomp® Online Drug Database for Medication Review and Drug-Drug Interaction Analysis within a Comprehensive Geriatric Assessment in Elderly Cancer Patients' Journal of Analytical Oncology 1, (1) 32-41 Publisher Site , DOI
(2012) 'Determination of an adequate screening tool for identification of vulnerable elderly head and neck cancer patients treated with radio(chemo)therapy' Journal of Geriatric Oncology 3, (1) 24-32 Publisher Site , DOI
(2009) 'Bile Acids Initiate Lineage‐Addicted Gastroesophageal Tumorigenesis by Suppressing the EGF Receptor‐AKT Axis' Clinical and Translational Science 2, (4) 286-293 Publisher Site , DOI
(2007) '‘Triple Negative’ Breast Cancer: a New Area for Phase III Breast Cancer Clinical Trials' Clinical Oncology 20, (1) 35-39 Publisher Site , DOI
(2007) 'Recurrent Low- to Intermediate-Grade Chondrosarcoma of the Thumb with Lung Metastases: An Objective Response to Trofosfamide' Oncology Research and Treatment 30, (4) 201-204 Publisher Site , DOI
(2006) 'Bile Acids Induce Ectopic Expression of Intestinal Guanylyl Cyclase C Through Nuclear Factor-κB and Cdx2 in Human Esophageal Cells' Gastroenterology 130, (4) 1191-1206 Publisher Site , DOI
(2003) 'Functional and molecular characterization of the epithelioid to round transition in human colorectal cancer LoVo cells' Oncogene 22, (46) 7199-7208 Publisher Site , DOI
(2003) 'Pathological staging and therapy of oesophageal and gastric cancer' Expert Opinion on Pharmacotherapy 4, (7) 1083-1096 Publisher Site , DOI
(2003) 'Pathological staging and therapy of oesophageal and gastric cancer' Expert Opinion on Pharmacotherapy 4, (7) 1083-1096 Publisher Site , DOI
(2002) 'Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways' Oncogene 21, (44) 6740-6750 Publisher Site , DOI
(2002) 'The new Sulindac derivative IND 12 reverses Ras-induced cell transformation' CANCER RESEARCH 62, (6) 1718-1723
(2001) 'The role of bile acids in carcinogenesis' Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 480-481, 359-369 Publisher Site , DOI
(2001) 'Single alteration of p53 or E-cadherin genes can alter the surgical resection benefit in an experimental model of colon cancer' Diseases of the Colon & Rectum 44, (8) 1106-1112 Publisher Site , DOI
(1999) 'The role of the E-cadherin/catenin complex in gastrointestinal cancer' ACTA GASTRO-ENTEROLOGICA BELGICA 62, (4) 393-402
Chapters
(2017) 'International Handbook of Positive Aging' in Docking RE; Stock J Routledge Publisher Site , DOI